Last mentioned: 4d ago
Former Fed Chair Ben Bernanke's appointment to Anthropic's independent trust adds deep economic firepower as the $965 billion AI firm eyes a public debut, focusing his Nobel-winning expertise on AI's macro impacts.
The immediate loss of 20 million barrels per day of oil is sending financial markets into uncharted territory. Inflationary expectations have unanchored, the IMF has slashed global growth forecasts, and central banks face an impossible trilemma between growth, inflation, and financial stability.
The Iran War’s 20-million-barrel daily oil disruption has jolted energy policies worldwide. The crisis is proving a double-edged sword for the climate: it accelerates renewable energy investments as an energy security imperative, yet also risks a coal resurgence and stretching green funding thin.
The U.S. government's AI contracts have more than tripled to over 1,700 in four years, with $90B in spending, yet fears about AI's societal impact mirror historical panics that led to policy mistakes. For AI developers and researchers, this tension could define the regulatory landscape.
The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors. With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
US lawmakers are raising alarms over the pharmaceutical industry's reliance on Chinese ingredients, warning that Beijing is applying its 'rare earths playbook' to dominate global medicine. A House Select Committee hearing highlighted concerns that China's control over active pharmaceutical ingredients and the biotech pipeline poses a strategic threat to American healthcare security.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.